Maternal RSV vaccine development. Where to from here?

Area of Science:

• Pediatrics
• Infectious Diseases
• Vaccinology

Background:

• Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infections in infants worldwide.
• Infant morbidity and mortality due to RSV are disproportionately high in low-income countries and in infants under six months old.
• Currently, no effective treatment exists for RSV infection, making prevention a critical public health priority.

Purpose of the Study:

• To review the current landscape of RSV prevention strategies.
• To highlight maternal RSV vaccination as a promising approach for protecting young infants.
• To discuss the implications of ongoing clinical trial results for public health policy.

Main Methods:

• Review of existing literature on RSV epidemiology and prevention.
• Analysis of the rationale and potential efficacy of maternal RSV vaccination.
• Consideration of public health implementation strategies for RSV vaccines.

Main Results:

• Monoclonal antibodies and vaccines are the primary methods for RSV prevention.
• Maternal vaccination has a strong precedent in protecting infants against other diseases.
• Phase III clinical trial data are crucial for informing vaccine implementation decisions.

Conclusions:

• Maternal RSV vaccination is a highly promising strategy to protect infants during their most vulnerable period.
• The implementation of RSV vaccines requires careful consideration alongside other public health measures.
• Further data from ongoing trials will guide the global strategy for reducing the burden of RSV disease.